Drug intelligence / Profile preview

Shuangshi Tonglin

Development stage: Unknown
Lead developer: Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Shuangshi Tonglin is a Traditional Chinese Medicine (TCM) botanical formulation, typically administered as capsules, used for the treatment of lower urinary tract conditions characterized by damp-heat symptoms. It is primarily indicated for chronic prostatitis, acute cystitis, and acute urethritis, which present with symptoms of lower urinary tract irritation such as frequency, urgency, and painful urination. The formulation was developed and studied by institutions including Dongzhimen Hospital of the Beijing University of Chinese Medicine and is manufactured by Guizhou Liangji Pharmaceutical. Its mechanism involves anti-inflammatory and antimicrobial properties derived from its herbal components, which traditionally aim to clear heat and promote diuresis. It is an NMPA-approved Chinese patent medicine (Zhong Cheng Yao).

Brand names: Shuangshi Tonglin
Other names: Shuangshi Tonglin CapsulesShuangshi Tonglin Jiaonang

Targets

SIRT1 (NAD-dependent protein deacetylase sirtuin-1)AMPK (Adenosine monophosphate–activated protein kinase)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)JNK (Mitogen-activated protein kinase kinase kinase family)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)MAPK14 (p38 mitogen-activated protein kinase alpha)NOX2/4 (NADPH oxidase 2 and NADPH oxidase 4)TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on Shuangshi Tonglin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuangshi Tonglin.

Explore the full profile